Article By:
ChinaBio® Today
Saturday, August 1, 2020 1:34 PM EDT
Shanghai Hansoh Pharma obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment, plus milestones of up to $68 million. It will also pay royalties on sales.